Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Evelo Biosciences (Nasdaq:EVLO) announced a conference call for March 24, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results and business highlights. The live call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international) with the conference ID 6076311. Evelo is focused on developing SINTAX™ medicines for inflammatory diseases, with three product candidates—EDP1815, EDP1867, and EDP2939—currently under development. More information is available on their website.
- Evelo is advancing three product candidates targeting inflammatory diseases.
- SINTAX™ medicines are positioned as novel treatments with system-wide therapeutic effects.
- None.
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights.
To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 6076311. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases.
Evelo currently has three product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contacts
Investors:
Kendra Sweeney, 239-877-7474
ksweeney@evelobio.com
Media:
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
When will Evelo Biosciences report its 2021 financial results?
What are Evelo's product candidates?
How can I access the Evelo conference call?
Where can I find more information about Evelo Biosciences?
